Axsome Therapeutics Files 8-K on Financials and Events
Ticker: AXSM · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1579428
Sentiment: neutral
Topics: financial-condition, operations-update, filing
Related Tickers: AXSM
TL;DR
AXSM dropped an 8-K detailing financials and other events. Check it out.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at One World Trade Center, New York, NY.
Why It Matters
This 8-K filing provides investors with crucial updates on Axsome Therapeutics' financial health and significant corporate events, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing providing financial and operational updates, not indicating immediate significant risk.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- One World Trade Center, 22nd Floor (address) — Principal Executive Offices
- New York (location) — City of Principal Executive Offices
- 10007 (zip_code) — Zip Code of Principal Executive Offices
- (212) 332-3241 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Axsome Therapeutics, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as Other Events, and to include Financial Statements and Exhibits.
On what date was this 8-K report filed?
The report was filed on January 13, 2025.
In which U.S. state is Axsome Therapeutics, Inc. incorporated?
Axsome Therapeutics, Inc. is incorporated in Delaware.
What is the address of Axsome Therapeutics, Inc.'s principal executive offices?
The principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
What is the telephone number listed for Axsome Therapeutics, Inc.?
The telephone number listed is (212) 332-3241.
Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-13 07:05:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20250113.htm (8-K) — 44KB
- axsm-ex99_1.htm (EX-99.1) — 18KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-25-004559.txt ( ) — 205KB
- axsm-20250113.xsd (EX-101.SCH) — 23KB
- axsm-20250113_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Axsome Therapeutics, Inc. (the "Company") issued a press release entitled "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue." For purposes of this Item 2.02, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. As reported above, on January 13, 2025, the Company issued a press release entitled "Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue." For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: January 13, 2025 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer